Impact of morin-5'-sulfonic acid sodium salt on cyclophosphamide-induced gastrointestinal toxicity in rats.
BACKGROUND
The aim of this study was to evaluate the effect of morin-5'-sulfonic acid sodium salt (NaMSA) on cyclophosphamide-induced gastrointestinal changes in rats.


METHODS
Rats received intragastrically 0.9% saline (group C), cyclophosphamide (15 mg/kg) (group CX), NaMSA (100 mg/kg) (group M) or cyclophosphamide (15 mg/kg) with NaMSA (100 mg/kg) (group M-CX), respectively, for 10 days.


RESULTS
No histological lesions were observed in the liver and the large intestine in the control group and group receiving NaMSA. In the cyclophosphamide-treated group, a generalized blurred trabecular structure, hepatocyte apoptosis, focal and diffuse necrosis were noticed in the liver and atypia of epithelial cells or adenoma were noticed in the large intestine. In the group receiving both cyclophosphamide and NaMSA, hepatocyte apoptosis in the liver was observed less frequently. Histological examination of the small intestine revealed: low-grade dysplasia adenoma in the C, M, CX and M-CX group (in 44%, 0%, 100%, and 55.6% of specimens, respectively) with adenocarcinoma in 55.6% of specimens in the cyclophosphamide-receiving group only. Adenoma with high-grade dysplasia was observed in the control and NaMSA-receiving group with a similar frequency (22%). In addition to the histological evaluation, blood cell count parameters, as well as total protein concentration, blood glucose level, amylase, ALT, AST and GGTP activities were evaluated. Cyclophosphamide impaired weight gain, decreased blood cell count parameters and total protein concentration, and increased the GGTP activity. Those changes were not reversed by NaMSA.


CONCLUSIONS
Summing up, NaMSA may protect against some cyclophosphamide-induced histological abnormalities in the gastrointestinal tract, including intestinal neoplasia in rats.
Department of Pharmacology, Wroclaw Medical University, Wrocław, Poland. Electronic address: anna.merwid-lad@umed.wroc.pl.
Anna
A
Merwid-Ląd
Department of Pharmacology, Wroclaw Medical University, Wrocław, Poland.
Dorota
D
Ksiądzyna
Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Wrocław, Poland.
Agnieszka
A
Hałoń
Department of Pharmacology, Wroclaw Medical University, Wrocław, Poland.
Ewa
E
Chlebda-Sieragowska
Department of Pharmacology, Wroclaw Medical University, Wrocław, Poland.
Małgorzata
M
Trocha
Department of Pharmacology, Wroclaw Medical University, Wrocław, Poland.
Marta
M
Szandruk
Department of Pharmacology, Wroclaw Medical University, Wrocław, Poland.
Tomasz
T
Sozański
Department of Pharmacology, Wroclaw Medical University, Wrocław, Poland.
Jan
J
Magdalan
Department of Inorganic and Analytical Chemistry, Chemical Faculty, University of Technology, Rzeszów, Poland.
Maria
M
Kopacz
Department of Inorganic and Analytical Chemistry, Chemical Faculty, University of Technology, Rzeszów, Poland.
Anna
A
Kuźniar
Department of Inorganic and Analytical Chemistry, Chemical Faculty, University of Technology, Rzeszów, Poland.
Dorota
D
Nowak
Department of Pharmacology, Wroclaw Medical University, Wrocław, Poland.
Małgorzata
M
Pieśniewska
Department of Pharmacology, Wroclaw Medical University, Wrocław, Poland.
Adam
A
Szeląg
D000236:Adenoma / Q000139:chemically induced / Q000188:drug therapy; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001772:Blood Cell Count; D001835:Body Weight / Q000187:drug effects; D003520:Cyclophosphamide / Q000009:adverse effects*; D005260:Female; D005419:Flavonoids / Q000494:pharmacology* / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control*; D022781:Hepatocytes / Q000187:drug effects / Q000473:pathology; D007420:Intestine, Large / Q000187:drug effects* / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D009336:Necrosis / Q000188:drug therapy / Q000473:pathology; D051381:Rats; D013451:Sulfonic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D005723:gamma-Glutamyltransferase / Q000097:blood
D005419:Flavonoids; D013451:Sulfonic Acids; C576986:morin-5'-sulfonic acid; D003520:Cyclophosphamide; D005723:gamma-Glutamyltransferase
Cyclophosphamide; Intestines; Liver; NaMSA; Toxicity